Clinical Trial Update: Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update on subcutaneous immunoglobulin for patients with primary immunodeficiency requiring IgG replacement; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: CSL Behring | Conditions: Primary Immune Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2013-01-25